Discordant effects of guanidines on renal structure and function and on regional vascular dysfunction and collagen changes in diabetic rats

Diabetes

Volumn 46, Issue 1, 1997, Pages 94-106

  Nyengaard, Jens R ^a,b   Chang, Katherine ^a   Berhorst, Susan ^a   Reiser, Karen M ^c   Williamson, Joseph R ^a   Tilton, Ronald G ^d  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AARHUS UNIVERSITY   (Denmark)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d TEXAS BIOTECHNOLOGY CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGUANIDINE; METHYLGUANIDINE;

ANIMAL EXPERIMENT; ARTICLE; COLLAGEN SYNTHESIS; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DRUG EFFECT; GLYCATION; HEMOGLOBIN DETERMINATION; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0031022947     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.46.1.94     Document Type: Article

References (102)

1. Baynes JW: Role of oxidative stress in the development of complications in diabetes. Diabetes 40:405-412, 1991
2. Miyata S, Monnier V: Immunohistochemical detection of advanced glycosylation end products in diabetic tissues using monoclonal antibody to pyrraline. J Clin Invest 89:1102-1112, 1992
3. Beisswenger PJ, Moore LL, Brinck-Johnsen T, Curphey TJ: Increased collagen-linked pentosidine levels and advanced glycosylation end products in early diabetic nephropathy. J Clin Invest 92:212-217, 1993
4. Brownlee M: Glycation and diabetic complications. Diabetes 43:836-841, 1994
5. Ziyadeh FN, Cohen MP: Effects of glycated albumin on mesangial cells: evidence for a role in diabetic nephropathy. Mol Cell Biochem 125:19-25, 1993
6. Lyons TJ, Li W, Wells-Knecht MC, Jokl R: Toxicity of mildly modified low-density lipoproteins to cultured retinal capillary endothelial cells and pericytes. Diabetes 43:1090-1095, 1994
7. Vlassara H, Bucala R, Striker L: Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 70:138-151, 1994
8. Vlassara H, Striker LJ, Teichberg S, Fuh H, Ming Li Y, Steffes M: Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Nalt Acad Sci USA 91:11704-11708, 1994
9. Bucala R, Cerami A, Vlassara H: Advanced glycosylation end products in diabetic complications: biochemical basis and prospects for therapeutic intervention. Diabetes Rev 3:258-268, 1995
10. Fu M-X, Wells-Knecht KJ, Blackledge JA, Lyons TJ, Thorpe SR, Baynes JW: Glycation, glycoxidation, and cross-linking of collagen by glucose. Diabetes 43:676-683, 1994
11. Edelstein D, Brownlee M: Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes 41:26-29, 1992
12. Picard S, Parthasarathy S, Fruebis J, Witztum JL: Aminoguanidine inhibits oxidative modification of low density lipoprotein protein and the subsequent increase in uptake by macrophage scavenger receptors. Proc Natl Acad Sci USA 89:6876-6880, 1992
13. Wolff SP, Jiang ZY, Hunt JV: Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Rad Biol Med 10:339-352, 1991
14. Jones AF, Winkles JW, Thornalley PJ, Lunec J, Jennings PE, Barnett AH: Inhibitory effect of superoxide dismutase on fructosamine assay. Clin Chem 33:147-149, 1987
15. Sakurai T, Tsuchiya S: Superoxide production from nonenzymatically glycated protein. FEBS Lett 236:406-410, 1988
16. Mullarkey CJ, Edelstein D, Brownlee M: Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Comm 173:932-939, 1990
17. Hunt JV, Bottoms MA, Mitchinson MJ: Oxidative alterations in the experimental glycation model of diabetes mellitus are due to protein-glucose adduct oxidation. Biochem J 291:529-535, 1993
18. Masumoto N, Tasaka K, Miyake A, Tanizawa O: Superoxide anion increases intracellular free calcium in human myometrial cells. J Biol Chem 265:22533-22536, 1990
19. Murrell AC, Francis MJO, Bromley L: Modulation of fibroblast proliferation by oxygen free radicals. Biochem J 265:659-665, 1990
20. Chandrakasan G, Bhatnagar RS: Stimulation of collagen synthesis in fibroblast cultures by superoxide. Cell Mol Biol 37:751-755, 1991
21. Ikebuchi Y, Masumoto N, Tasaka K, Koike K, Kasahara K: Superoxide anion increases intracellular pH, intracellular free calcium, and arachidonate release in human amnion cells. J Biol Chem 266:13233-13237, 1991
22. Kashihara N, Watanabe Y, Makino H, Wallner EI, Kanwar YS: Selective decreased de novo synthesis of glomerular proteoglycans under the influence of reactive oxygen species. Proc Natl Acad Sci USA 89:6309-6313, 1992
23. Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T, Nyengaard JR, Van den Enden M, Kilo C, Tilton RG: Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 42:801-813, 1993
24. Schayer RW: Catabolism of histamine in vivo. In Handbook of Experimental Pharmacology. Rocha e Silva M, Ed. Berlin, Springer-Verlag, 1966, p. 672-683
25. Tilton RG, Chang K, Hasan KS, Smith SR, Petrash JM, Misko TP, Moore WM, Currie MG, Corbett JA, McDaniel ML, Williamson JR: Prevention of diabetic vascular dysfunction by guanidines: inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes 42:221-232, 1993
26. Misko TP, Moore WM, Kasten TP, Nickols GA, Corbett JA, Tilton RG, McDaniel ML, Williamson JR, Currie MG: Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur J Pharmacol 233:119-125, 1993
27. Corbett JA, Tilton RG, Chang K, Hasan KS, Ido Y, Wang JL, Sweetland MA, Lancaster JR Jr, Williamson JR, McDaniel ML: Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 41:552-556, 1992
28. Hasan KS, Chang K, Allison W, Faller A, Santiago JV, Tilton RG, Williamson JR: Glucose-induced increases in ocular blood flow are prevented by aminoguanidine and L-NMMA, inhibitors of nitric oxide synthase (Abstract). Invest Ophthalmol Vis Sci 34:1127, 1993
29. Williamson JR, Chang K, Allison W, Faller AM, Santiago JV, Tilton RG, Hasan KS: Increased blood flow in retina, sciatic nerve, and kidney in hyperglycemic nondiabetic rats: role of nitric oxide (Abstract). Diabetologia 36 (Suppl. 1):A51, 1993
30. Cross AH, Misko TP, Lin RF, Hickey WF, Trotter JL, Tilton RG: Aminoguanidine, an inhibitor of inducible nitric oxide synthase, ameliorates experimental autoimmune encephalomyelitis in SJL mice. J Clin Invest 93:2684-2690, 1994
31. Tilton RG, Chang K, Corbett JA, Misko TP, Currie MG, Bora NS, Kaplan HJ, Williamson JR: Endotoxin-induced uveitis in the rat is attenuated by inhibition of nitric oxide production. Invest Ophthalmol Vis Sci 35:3278-3288, 1994
32. Worrall NK, Lazenby WD, Misko TP, Lin T-S, Rodi CP, Manning PT, Tilton RG, Williamson JR, Ferguson TB Jr: Modulation of in vivo alloreactivity by inhibition of inducible nitric oxide synthase. J Exp Med 181:63-70, 1995
33. Tilton RG, Chang K, Pugliese G, Eades DM, Province MA, Sherman WR, Kilo C, Williamson JR: Prevention of hemodynamic and vascular albumin filtration changes in diabetic rats by aldose reductase inhibitors. Diabetes 38:1258-1270, 1989
34. Nyengaard JR, Bendtsen TF: Glomerular number in a range of animals estimated by a simple and unbiased stereological method. Acta Stereol 9:245-253, 1990
35. 125I-albumin permeation in retinas of chronically diabetic rats (Abstract). Diabetes 41:21A, 1992
36. Oturai P, Hasselager E, Myrup B, Kofoed-Enevoldsen A, Thomsen M, Deckert T: Increased rate of kidney tumors in aminoguanidine treated STZ-diabetic rats (Abstract). Diabetes 43:204A, 1994
37. Gundersen HJG: Notes on the estimation of numerical density of arbitrary profiles: the edge effect. J Microsc 111:219-223, 1977
38. Østerby R, Gundersen HJG: Sampling problems in the kidney. In Lecture Notes in Biomathematics. Miles RW, Serra J, Eds. Berlin, Springer-Verlag, 1978, p. 185-191
39. Østerby R, Gundersen HJG: Fast accumulation of basement membrane material and the rate of morphological changes in acute experimental diabetic glomerular hypertrophy. Diabetologia 18:493-500, 1980
40. Jensen EB, Gundersen HJG, Østerby R: Determination of membrane thickness distribution from orthogonal intercepts. J Microsc 115:19-33, 1979
41. Kroustrup JP, Gundersen HJG: Sampling problems in an heterogeneous organ: quantitation of relative and total volume of pancreatic islets by light microscopy. J Microsc 132:43-55, 1983
42. Gundersen HJG, Østerby R: Optimizing sampling efficiency of stereological studies in biology: or "do more less well." J Microsc 121:65-73, 1980
43. Monnier VM, Wishwanath V, Frank KE, Elmets CA, Dauchot P, Kohn RR: Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. N Engl J Med 314:403-408, 1986
44. Reiser KM: Influence of age and long-term dietary restriction on enzymatically mediated crosslinks and nonenzymatic glycation of collagen in mice. J Gerontol Biol Sci 49:B71-B79, 1994
45. Wbessner JF Jr: The determination of hydroxyproline in tissue and protein samples containing small proportions of this amino acid. Arch Biochem Biophys 93:440-447, 1961
46. Sell DR, Monnier VM: Structure elucidation of a senescence cross-link from human extracellular matrix. J Biol Chem 264:21597-21602, 1989
47. Sell DR, Monnier VM: End-stage renal disease and diabetes catalyze the formation of a pentose-derived crosslink from aging human collagen. J Clin Invest 85:380-384, 1990
48. Anderson TW: An Introduction to Multivariate Statistical Analysis. New York, Wiley, 1958
49. Lehmann EL: Nonparametrics. In Statistical Methods Based on Ranks. San Francisco, Holden-Day, 1975
50. Blom G: Statistical Estimates and Transformed Beta Variables. New York, Wiley, 1958
51. Miller RG Jr: Simultaneous Statistical Inference. Berlin, Springer-Verlag, 1981
52. Schmidt RE, Dorsey DA, Beaudet LN, Reiser KM, Willlamson JR, Tilton RG: Effect of aminoguanidine on the frequency of neuroaxonal dystrophy in the superior mesenteric sympathetic autonomie ganglia of rats with streptozocin diabetes. Diabetes 45:284-290, 1996
53. Pugliese G, Tilton RG, Chang K, Speedy A, Province MA, Eades DM, Lacy PE, Kilo C, Williamson JR: Effects of islet isografts on hemodynamic and vascular filtration changes in diabetic rats. Diabetes 39:323-332, 1990
54. Pugliese G, Tilton RG, Speedy A, Chang K, Santarelli E, Province MA, Eades D, Sherman WR, Williamson JR: Effects of very mild versus overt diabetes on vascular hemodynamics and barrier function in rats. Diabetologia 32:845-857, 1990
55. Tilton RG, Pugliese G, Faller AM, LaRose LS, Province MA, Williamson JR: Interactions between hypertension and diabetes on vascular function and structure in rats. J Diab Comp 6:187-196, 1992
56. Ido Y, Chang K, Ostrow E, Allison W, Kilo C, Tilton RG: Aminoguanidine prevents regional blood flow increases in streptozotocin-diabetic rats (Abstract). Diabetes 39 (Suppl. 1):93A, 1990
57. Pugliese G, Tilton RG, Williamson JR: Glucose-induced metabolic imbalances in the pathogenesis of diabetic vascular disease. Diabetes Metab Rev 7:35-59, 1991
58. Bucala R, Tracey KJ, Cerami A: Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 87:432-438, 1991
59. Lash JM, Bohlen HG: Structural and functional origins of suppressed acetylcholine vasodilation in diabetic rat intestinal arterioles. Cir Res 69:1259-1268, 1991
60. McNally PG, Watt PAC, Rimmer T, Burden AC, Hearnshaw JR, Thurston H: Impaired contraction and endothelium-dependent relaxation in isolated resistance vessels from patients with insulin-dependent diabetes mellitus. Clin Sci 87:32-36, 1994
61. Taylor PD, Graves JE, Poston L: Selective impairment of acetylcholine-mediated endothelium-dependent relaxation in isolated resistance arteries of the streptozotocin-induced diabetic rat. Clin Sci 88:519-524, 1995
62. Cohen MP, Clements RS, Cohen JA, Shearman CW: Prevention of decline in renal function in the diabetic db/db mouse. Diabetologia 39:270-274, 1996
63. Wu V-Y, Cohen MP: Receptors specific for amadori-modified glycated albumin on murine endothelial cells. Biochem Biophys Res Comm 198:734-739, 1994
64. Wu V-Y, Cohen MP: Evidence for a ligand receptor system mediating the biologic effects of glycated albumin in glomerular mesangial cells. Biochem Biophys Res Comm 207:521-528, 1995
65. Krantz S, Brandt R, Gromoll B: Binding sites for short-term glycated albumin on peritoneal cells of the rat. Biochim Biophys Acta 1177:15-24, 1993
66. Salazar R, Brandt R, Krantz S: Expression of fructosyllysine receptors on human monocytes and monocyte-like cell lines. Biochim Biophys Acta 1266:57-63, 1995
67. Krantz S, Salazar R, Brandt R, Kellermann J, Lottspeich F: Purification and partial amino acid sequencing of a fructosyllysine-specific binding protein from cell membranes of the monocyte-like cell line U937. Biochim Biophys Acta 1266:109-112, 1995
68. Schmidt AM, Hori O, Brett J, Yan SD, Wautier J-L, Stern D: Cellular receptors for advanced glycation end products: implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb 14:1521-1528, 1994
69. Tilton RG, Pugliese G, LaRosse LS, Faller AM, Chang K, Province MA, Williamson JR: Discordant effects of the aldose reductase inhibitor, sorbinil, on vascular structure and function in chronically diabetic and galactosemic rats. J Diab Complications 5:230-237, 1991
70. Tilton RG, Faller AM, LaRose LS, Burgan J, Williamson JR: Dietary myo-inositol supplementation does not prevent retinal and glomerular vascular structural changes in chronically diabetic rats. J Diab Complications 7:188-198, 1993
71. Itakura M, Yoshikawa H, Bannai C, Kato M, Kunika K, Kawakami Y, Yamaoka T, Yamashita K: Aminoguanidine decreases urinary albumin and high-molecular-weight proteins in diabetic rats. Life Sci 49:889-897, 1991
72. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G: Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 40:1328-1334, 1991
73. Edelstein D, Brownlee M: AminoguanidIne ameliorates albuminuria in diabetic hypertensive rats. Diabetologia 35:96-97, 1992
74. Soulis-Liparota T, Cooper ME, Dunlop M, Jerums G: The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. Diabetologia 38:387-394, 1995
75. Soulis T, Cooper M, Layton G, Allen T, Jerums G: Aminoguanidine reduces tissue fluorescence but not albuminuria in diabetic rats. In Glycated Proteins in Diabetes Mellitus. Ryal RG, Ed. Adelaide, Australia, University of Adelaide, 1988, p. 310-320
76. Huijberts MSP, Wolffenbuttel BHR, Crijns FRL, Nieuwenhuijzen Kruseman AC, Bemelmans MA, Struijker Boudier HAJ: Aminoguanidine reduces regional albumin clearance but not urinary albumin excretion in streptozotocin-diabetic rats. Diabetologia 37:10-14, 1994
77. Steffes MW, Mauer SM: Diabetic glomerulopathy in man and experimental animal models. Int Rev Exp Pathol 26:147-175, 1984
78. Seyer-Hansen K: Renal hypertrophy in experimental diabetes mellitus. Kidney Int 23:643-646, 1983
79. Ellis EN, Good BH: Prevention of glomerular basement membrane thickening by aminoguanidine in experimental diabetes mellitus. Metabolism 40:1016-1019, 1991
80. Brownlee M, Cerami A, Vlassara H: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318:1315-1321, 1988
81. Mauer SM, Steffes MW, Ellis EN, Sutherland DER, Brown DM, Goetz FC: Structural-functional relationships in diabetic nephropathy. J Clin Invest 74:1143-1155, 1984
82. Ellis EN, Steffes MW, Goetz FC, Sutherland DER, Mauer SM: Glomerular filtration surface in type I diabetes mellitus. Kidney Int 29:889-894, 1986
83. McVerry BA, Hopp A, Fisher C, Huehns ER: Production of pseudodiabetic renal glomerular changes in mice after repeated injections of glucosylated proteins. Lancet i:738-740, 1980
84. Sabbatini M, Sansone G, Uccello F, Giliberti A, Conte G, Andreucci VE: Early glycosylation products induce glomerular hyperfiltration in normal rats. Kidney Int 42:875-881, 1992
85. Richard S, Tamas C, Sell DR, Monnier VM: Tissue-specific effects of aldose reductase inhibition on fluorescence and cross-linking of extracellular matrix in chronic galactosemia: relationship to pentosidine cross-links. Diabetes 40:1049-1056, 1991
86. Sell DR, Carlson EC, Monnier VM: Differential effects of type 2 (non-insulin-dependent) diabetes mellitus on pentosidine formation in skin and glomerular basement membrane. Diabetologia 36:936-941, 1993
87. Reiser KM, Tilton RG, Williamson J: The effects of aminoguanidine on enzymatically mediated crosslinking and nonenzymatic glycation of collagen in experimental diabetes in rats: in vivo and in vitro studies. Biochem (Life Sci Adv) 12:37-45, 1993
88. Schneir M, Bowersox J, Ramamurthy N, Yavelow J, Murray J, Edlin-Folz E, Golub L: Response of rat connective tissues to streptozotocin-diabetes: tissue-specific effects on collagen metabolism. Biochim Biophys Acta 583:95-102, 1979
89. Schneir M, Ramamurthy N, Golub L: Skin collagen metabolism in the streptozotocin-induced diabetic rat: enhanced catabolism of collagen formed both before and during the diabetic state. Diabetes 31:426-431, 1982
90. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A: Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232:1629-1632, 1986
91. Paz MA, Keith DA, Traverso HP, Gallop PM: Isolation, purification and crosslinking profiles of elastin from lung and aorta. Biochemistry 15:4912-4918, 1976
92. Rucker RB, Tinker D: Structure and metabolism of arterial elastin. Int Rev Exp Pathol 17:1-47, 1977
93. Seglen PO: Preparation of isolated rat liver cells. Meth Cell Biol 13:29-83, 1976
94. Odetti PR, Borgoglio A, DePascale A, Rolandi R, Adezati L: Prevention of diabetes-increased aging effect on rat collagen-linked fluorescence by aminoguanidine and rutin. Diabetes 39:796-801, 1990
95. Ido Y, McHowat J, Chang KC, Arrigoni-Martelli E, Orfalian Z, Kilo C, Corr PB, Williamson JR: Neural dysfunction and metabolic imbalances in diabetic rats: prevention by acetyl-L-carnitine. Diabetes 43:1469-1477, 1994
96. Van den Enden MK, Nyengaard JR, Ostrow E, Burgan JH, Williamson JR: Elevated glucose levels increase retinal glycolysis and sorbitol pathway metabolism: implications for diabetic retinopathy. Invest Ophthalmol Vis Sci 36:1675-1685, 1995
97. Tilton RG, Baier LD, Harlow JE, Smith SR, Ostrow E, Williamson JR: Diabetes-induced glomerular dysfunction: links to a more reduced cytosolic redox state. Kidney Int 41:778-788, 1992
98. Williamson JR, Kawamura T, Kilo C, Van den Enden M, Nyengaard JR, Ido Y, Tilton RG: Current concepts of the role of polyol metabolism and related metabolic abnormalities in diabetic complications. In Pathogenesis and Treatment of NIDDM and Its Related Problems. Sakamoto N, Alberti KGMM, Hotta N, Eds. Amsterdam, Elsevier Science Publishers, 1994, p. 75-81
99. Salvemini D, Misko TP, Masferrer JL, Seibert K, Currie MG, Needleman P: Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci USA 90:7240-7244, 1993
100. Corbett JA, Kwon G, Turk J, McDaniel ML: IL-1β induces the coexpression of both nitric oxide synthase and cyclooxygenase by islets of langerhans: activation of cyclooxygenase by nitric oxide. Biochemistry 32:13767-13770, 1993
101. Bleyer AJ, Fumo P, Snipes ER, Goldfarb S, Simmons DA, Ziyadeh FN: Polyol pathway mediates high glucose-induced collagen synthesis in proximal tubule. Kidney Int 45:659-666, 1994
102. International Agency for Research on Cancer (IARC): Streptozotocin. In IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Man: Some Aromatic Amines, Hydrazine and Related Substances, N-Nitroso Compounds and Miscellaneous Alkylating Agents. Vol. 4. Lyon, World Health Organization, 1974, p. 221-227